Phaseline

Companies › Kerecis

Kerecis: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MariGen (Intact Fish Skin Graft)
Biological wound dressing derived from fish skin
–Phase 4Venous Leg Ulcer (VLU)Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06693570MariGen (Intact Fish Skin Graft)Phase 4Venous Leg Ulcer (VLU)CardiovascularNov 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cell Biopeutics Resources Sdn Bhd TR Therapeutics AOTI Beijing Inno Medicine Nectero Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.